Drugs / Calcium dobesilate capsules
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05007262 Comparator | Aug 2021 → Oct 2023 | diabetic retinopathy, type 2 diabetes mellitus | Guizhou Bailing Group Pharmaceutical Co Ltd | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Calcium dobesilate capsules | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05007262 ↗ |
| Route | Oral | “Calcium dobesilate capsules, 1 capsule at a time, tid,po.(morning, midday, and evening), used on an empty stomach.” NCT05007262 ↗ |